Curis Names Ali Fattaey CEO - Quick Facts

(RTTNews) - Curis, Inc. (CRIS), an oncology-focused company developing novel drug candidates for the treatment of human cancers, announced the appointment of Ali Fattaey, Ph.D. as the company's President and Chief Executive Officer and as a member of its Board of Directors.

Dr. Fattaey formerly served as the company's President and Chief Operating Officer. He will succeed Dan Passeri following his resignation from the position of CEO, which was also announced today.

Passeri has been appointed Vice Chairman of Curis' Board of Directors and will also serve as a strategic advisor to Curis.

Dan Passeri said, "It has been my pleasure working closely with Ali, and I am highly confident that Curis and its' shareholders will continue to benefit from Ali's leadership and vision as he assumes these additional responsibilities."